The mechanism, efficacy, and tolerability profile of agomelatine
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Agomelatine is a novel antidepressant that acts as a melatonin MT1 and MT2 receptor agonist and serotonin 5-HT2C receptor antagonist, putatively reversing circadian rhythm disruption in major depressive disorder (MDD) and promoting dendritic neurogenesis in animal models of depression. It may be a preferable alternative to antidepressants currently in use due to its improved tolerability profile. AREAS COVERED: The PubMed database was searched for published randomized controlled trials (RCTs) evaluating the efficacy of agomelatine as well as its tolerability and safety in the treatment of MDD. The key search term used was agomelatine combined with major depressive disorder/depressive disorder/depression and antidepressant. Article selection was based upon sample size and overall methodological quality. EXPERT OPINION: Agomelatine is a multi-modal agent with novel mechanisms of action, having sound evidence supporting its overall statistical efficacy and adequate tolerability profile for MDD treatment. However, the clinical significance of agomelatine has been contested, calling for additional studies in evaluation of its effect size. Of further concern are reported transient elevations in transaminases and severe but rare liver reactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894 · cited 2×
“This is supported by evidence that CLOCK modulates activity of the anterior cingulate cortex during an emotional task in depressed patients [17,18].”
BackgroundAntidepressants and Body Weight: A Comprehensive Review and Meta-Analysis
Serretti, A., & Mandelli, L. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05346blu · Cited by 621
Montejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., et al. (1997) · Journal of Sex & Marital Therapy · doi:10.1080/00926239708403923 · Cited by 505 · cited 1×
“Sexual dysfunction is reported in approximately 60% of individuals receiving fluoxetine, paroxetine, sertraline, or fluvoxamine when asked directly by their physician [41].”
BackgroundBipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide
Savitz, J., & Drevets, W. C. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.01.004 · Cited by 494 · cited 1×
“In addition, decreased prefrontal cortex activity and increased limbic activity have been shown to be common to circadian disorders and MDD [12], suggesting they may involve common underlying neurocircuits.”
BackgroundGoodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Circadian misalignment in major depressive disorder
Emens, J., Lewy, A., Kinzie, J. M., Arntz, D., & Rough, J. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2009.04.009 · Cited by 253
Fava, M., Graves, L. M., Benazzi, F., Scalia, M. J., Iosifescu, D. V., Alpert, J. E., & Papakostas, G. I. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1113 · Cited by 229
The effects of depression and age on the Horne-Ostberg morningness-eveningness score
Drennan, M. D., Klauber, M. R., Kripke, D. F., & Goyette, L. M. (1991) · Journal of Affective Disorders · doi:10.1016/0165-0327(91)90096-b · Cited by 215 · cited 1×
“, people who prefer to go to bed late are most alert in the late evening hours) [8], with degree of chronotype also exhibiting correlation with MDD severity [9].”
BackgroundMichelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181 · cited 1×
“Furthermore, adverse events resulting from significant dose alteration or cessation of antidepressant use have been commonly observed with fluoxetine, paroxetine, and sertraline [44], commonly referred to as discontinuation syndrome.”
BackgroundModell, S., Ising, M., Holsboer, F., & Lauer, C. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.004 · Cited by 103 · cited 1×
“2 Neural activity Decreased rapid eye movement (REM) with increased REM density during sleep has been observed in both MDD patients and those at familial risk for MDD [11].”
Background
Cited by
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
“For example, some relatively new antidepressants have an important (antagonist) action at 5-HT2C receptors (which has secondary faciliatory effects on DA transmission) (MacIsaac et al., 2014) and others, such as vortioxetine, have appreciable affinities for several other 5-HT receptors (Riga et al.”
BackgroundPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Circadian Disruption in Psychiatric Disorders
Jones, S. G., & Benca, R. M. (2015) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2015.07.004 · Cited by 86
Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
Levitan, M., Papelbaum, M., & E Nardi, A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s67470 · Cited by 25
Metadata
- Authors
- MacIsaac, S. E., Carvalho, A. F., Cha, D. S., Mansur, R. B., & McIntyre, R. S.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2013-12-16
- Volume
- 15
- Issue
- 2
- Pages
- 259-274
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2114843189
- Cited by
- 24
- References
- 12
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The mechanism, efficacy, and tolerability profile of agomelatine. https://app.cochat.ai/papers/10.1517/14656566.2014.862233
- The paper
- MacIsaac, S. E., Carvalho, A. F., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014). The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2014.862233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.